Abstract
LX1606 is an orally-delivered inhibitor of the rate-limiting enzyme in 5-HT synthesis, tryptophan hydroxylase (TPH). LX1606 has been shown in preclinical, as well as studies in healthy volunteers, to reduce peripheral 5-HT production. In humans this is evidenced by reductions in 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) and blood 5-HT concentrations. Reducing the amount of 5-HT produced by metastatic carcinoid tumors may reduce many of the symptoms and sequelae commonly associated with carcinoid syndrome. LX1606 (aka LX1032), offers a potentially novel therapeutic approach to CS palliation.
